Roy Baynes Sells Shares of Travere Therapeutics

On June 12, 2026, Roy Baynes sold 4,500 shares of Travere Therapeutics, Inc. (NasdaqGM: TVTX). This transaction was not part of a planned sale. Shares of Travere Therapeutics are currently trading at $53.80.

Insider Buying and Selling at Travere Therapeutics, Inc.

In addition to Roy Baynes, Timothy Coughlin also made moves in Travere Therapeutics stock on the same day. Coughlin sold 10,000 shares at an average price of $50.07, while earlier, both Baynes and Coughlin had purchased shares at lower prices. Baynes bought 4,500 shares at $21.38, and Coughlin acquired 10,000 shares at $26.52.

Other Institutional Activity in Travere Therapeutics

In recent institutional activity, Janus Henderson Group PLC increased its holdings by 908,420 shares to a total of 11,419,586 shares, valued at approximately $339.2 million. FMR LLC also boosted its stake by 1,350,104 shares, ending with 10,967,967 shares worth about $325.9 million. On the other hand, BlackRock, Inc. trimmed its position by 77,319 shares, now holding 7,792,033 shares valued at $231.5 million. Meanwhile, Armistice Capital, LLC significantly increased its holdings by 1,133,526 shares to a total of 4,897,417 shares, valued at around $145.5 million.

Travere Therapeutics Stock Snapshot

Shares of Travere Therapeutics, Inc. (NasdaqGM: TVTX) are currently trading near $53.80. The company has a market cap of approximately $5 billion and a forward P/E ratio of 11.08. With a beta of 1.141, the stock's 52-week range spans from $13.88 to $53.88. The 50-day moving average is $42.45, and the 200-day moving average is $33.07. Travere's current ratio is 3.131, with a quick ratio of 2.816 and a debt-to-equity ratio of 331.884.

Recent Earnings

Travere Therapeutics reported revenue of $536.2 million, reflecting a growth rate of 55.6%. Despite this, the company has a net margin of -3.995% and a return on equity of -69.383%. The next earnings report is scheduled for August 6, 2026.

Analysts Set New Price Targets

On June 15, 2026, Citigroup maintained its buy rating on Travere Therapeutics with a price target of $70. Wells Fargo also maintained a buy rating on June 12, with a target of $65. Other firms like HC Wainwright & Co. and TD Cowen have similarly maintained their buy ratings, with price targets of $67 and $60, respectively. The consensus among 14 analysts is a strong buy, with a mean target price of $56.14.

About Travere Therapeutics

Travere Therapeutics, Inc. is a biopharmaceutical company based in San Diego, California. It focuses on developing therapies for rare kidney and metabolic diseases. The company's products include FILSPARI, targeting IgA Nephropathy, and Thiola for cystinuria. Travere is also working on investigational treatments like Sparsentan and Pegtibatinase. Dr. Eric M. Dube, Ph.D., leads the company as CEO, with a team of 497 employees.

Bottom Line

Roy Baynes' recent sale of Travere Therapeutics shares is part of a broader pattern of insider transactions. Travere's stock is currently performing strongly, reflecting its promising pipeline and recent institutional interest. Analysts remain bullish, maintaining strong buy ratings and setting optimistic price targets. As always, 13F filings and insider trades provide valuable insights into investor sentiment and company performance.